HEMEO develops AI-based clinical decision support applications for coagulation management. This technology consolidates multi-source patient data into actionable insights for clinicians managing bleeding and thrombosis risks. The platform aims to personalize prevention and treatment protocols, potentially reducing morbidity, mortality, and the need for blood transfusions.
Funding
Funding not disclosed
Founders
Product
Problem
Clinicians face challenges in synthesizing diverse patient data to effectively manage coagulation complications, leading to potential delays in personalized treatment and suboptimal patient outcomes. The fragmented nature of medical information hinders timely and confident clinical decision-making regarding bleeding and thrombosis risks.
Solution
HEMEO provides an AI-powered clinical decision support platform designed to personalize the prevention and treatment of coagulation disorders. The system integrates data from multiple sources, presenting actionable insights to clinicians for early intervention. By leveraging AI, HEMEO aims to reduce patient morbidity and mortality associated with coagulation complications, improve recovery rates, and contribute to cost savings within healthcare systems. The platform facilitates a more proactive approach to managing hemostasis, enabling clinicians to make informed decisions with greater confidence.
Target Audience
The primary users are healthcare professionals, including physicians and specialists involved in patient care where coagulation status is critical, such as in intensive care units, surgery, and hematology.
Features
- AI-driven clinical decision support for personalized coagulation management.
- Data aggregation engine that consolidates information from disparate sources.
- Predictive analytics for identifying bleeding and thrombosis risks.
- Workflow integration designed to support early clinical intervention.
- Focus on improving patient recovery and survival rates.
- Tools to assist in reducing the need for blood transfusions.